enterobacteriaceae

WCK-4234 sodium (WCK 4234) is an inhibitor of β-lactamase can be used in studies targeting MDR infections. WCK-4234 sodium inhibits class A, C, and D β-lactamases and OXA carbapenemases.

Relebactam (MK-7655) is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases.

Zidebactam (WCK-5107) is a β-lactamase inhibitor and a penicillin-binding protein 2 (PBP2) inhibitor (IC50 = 0.26 μg/ml), with enzymatic inhibitory activity, and can be used for antibacterial research.

Tigemonam is a monobactam, a novel orally administered monobactam that protects against gram-negative aerobic bacterial pathogens and is at least as active against clinical isolates of Enterobacteriaceae as amitraz or carmonan (MIC90: 0.06-16 mg/l). [3]

Plazomicin is a next-generation aminoglycoside that has been designed as an antibiotic to avoid resistance through aminoglycoside-modifying enzymes. Plazomicin shows high activity against the Enterobacteriaceae.

Glycosyltransferase-IN-1 is a glycosyltransferase inhibitor with bacteriostatic activity, inhibiting MSSA, MRSA, Bacillus subtilis, and Enterobacteriaceae.

Cefmenoxime hydrochloride (Cefmenoxime hemihydrochloride) is a cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date, no severe side effects have been noted.

Cefmenoxime is a cephalosporin antibiotic administered intravenously or intramuscularly. It is an effective inhibitor of Enterobacteriaceae and is resistant to beta-lactamase-initiated hydrolysis. It is active against most common gram-positive and gram-ne

LYS228 (also known as Ancremonam) is a potent antibiotic effective against carbapenem-resistant Enterobacteriaceae bacteria (MIC90 = 2 uM/mL). It demonstrates strong antibacterial activity against CRE isolates even in the presence of all classes of β-lactamases.

Plazomicin (ACHN 490) sulfate is a potent aminoglycoside antibiotic that combats antibiotic resistance. It exhibits in vitro activity against various multidrug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae. Plazomicin sulfate is utilized for treating multidrug-resistant complicated urinary tract infections (cUTIs) and is studied for use in severe carbapenem-resistant Enterobacteriaceae infections.

ANT2681 is a potent NDM inhibitor with a Ki value of 0.04 μM for NDM-1. It also inhibits other MBLs such as VIM-1 and IMP-1, with Ki values of 0.63 μM and 3.81 μM, respectively. ANT2681 can be used in combination with Meropenem to suppress infections caused by NDM-producing Enterobacteriaceae.

ZN148 is a synthetic chelatable zinc metallo-β-lactamase (MBL) inhibitor that can reduce carbapenem resistance mediated by MBLs. It is capable of restoring the in vitro clinical sensitivity to carbapenems in over 98% of strains in an internationally large MBL-producing clinical Enterobacteriaceae strain collection. ZN148 is applicable for research on MBL-producing bacteria.

ANT3310 is a broad-spectrum covalent inhibitor of serine β-lactamase (Serine β-Lactamase) with an IC50 range of 1 nM to 175 nM against various serine β-lactamases. ANT3310 enhances the efficacy of β-lactam antibiotics against carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB). It is applicable for studies related to bacterial infections.

BAY-Y 3118 hydrochloride is a quinolone antibacterial agent with a broad spectrum of activity in vitro. It exhibits high efficacy against Gram-positive cocci and anaerobic bacteria, and shows moderate activity against Enterobacteriaceae and Pseudomonas aeruginosa. BAY-Y 3118 hydrochloride is utilized for research into infectious diseases.

rel-Avibactam (NXL-104) sodium is a β-lactamase inhibitor with broad-spectrum antibacterial activity. When combined with Ceftazidime, rel-Avibactam sodium exhibits significant inhibitory effects on Enterobacteriaceae producing Ambler class A and C β-lactamases. Its IC50 values are significantly lower than those of commonly used β-lactamase inhibitors like Clavulanic acid and Ticarcillin, demonstrating high efficacy against TEM-1 and P99 enzymes.

Cefdaloxime, an orally active cephalosporin and the metabolite of HR-916 ester, exhibits broad-spectrum antibacterial activity. It is effective against various pathogens, including most members of the Enterobacteriaceae family, Staphylococcus species, Streptococcus species, Neisseria gonorrhoeae, Moraxella catarrhalis, and Haemophilus influenzae.

LYS228 is a potent antibiotics against Carbapenem-Resistant Enterobacteriaceae (MIC90 = 2 uM/mL). LYS228 is potent in the presence of all classes of beta-lactamases.

Aerobactin is a bacterial-produced iron carrier and iron chelator, a key virulence factor in many Enterobacteriaceae bacteria, widely used in biochemical research.

BMS 180680 is a novel catechol-containing monolactam antibacterial active agent, which is the most effective compound against many species of Enterobacteriaceae.

CP 99433 is a new C-7 diazabicyclofluoroquinolone with a broad spectrum of activity that includes Enterobacteriaceae, Gram-positive cocci, and nonenteric Gram-negative bacilli.

Isepamicin (Sch 21420) is a potent aminoglycoside antibacterial compound with enhanced efficacy against strains harboring type I 6'-acetyltransferase. Its antibacterial spectrum encompasses Enterobacteriaceae and staphylococci, while exhibiting resistance against anaerobes, Neisseriaceae, and streptococci. Moreover, Isepamicin displays a robust concentration-dependent bactericidal effect, a prolonged post-antibiotic effect lasting several hours, and is capable of inducing adaptive resistance.

Avibactam sodium hydrate (NXL-104 hydrate) is a highly effective β-lactamase inhibitor that inhibits β-lactamases TEM-1 and CTX-M-15, as well as the carbapenemase produced by Klebsiella pneumoniae and carbapenem-resistant Enterobacteriaceae.

Cefmenoxime sodium is the ssalt form of Cefmenoxime (free base), a cephalosporin antibiotic administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms. It is a potent inhibitor of Enterobacteriaceae, and is resistant to beta-lactamase-initiated hydrolysis. The drug has a high success rate against many types of infection.

NOSO-95C is an antibacterial compound that bind to the bacterial ribosome and kill bacteria through inhibition of the translation. NOSO-95C showed promising in vitro and in vivo efficacy against Enterobacteriaceae.